Drugs / Measles, mumps and rubella Combined Vaccine, Live
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03160820 | Mar → Dec 2016 | measles, mumps infectious disease, post-vaccinal encephalitis, rubella | Centers for Disease Control and Prevention, China | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Measles, mumps and rubella Combined Vaccine, Live | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03160820 ↗ |
| Known as | MMR | “This study will evaluate the immunogenicity and safety of Beijing Tiantan's MMR vaccine in subjects 18 months of age and older.” NCT03160820 ↗ |
| Modality | Vaccine | “The MMR vaccine may be administered as a second dose to 4-6 year-old persons with one dose immunization with MMR vaccine or as a first dose to 18 month-old subjects with one...” NCT03160820 ↗ |